- US: +1-408-610-2300
- Toll Free: +1-866-831-4085
- Become a Client
The global single-use bioprocessing market size is expected to be valued at USD 79.47 billion by 2030, registering a CAGR of 16.6% from 2022 to 2030. Some of the leading factors driving the market trends include the surging demand for biopharmaceuticals and the need to attain energy efficiency, the need to reduce water wastage, and the risk of cross-contamination. Most biopharmaceutical entities are adopting single-use bioprocessing technology owing to the single-use bioprocessing systems that increase the efficiency in the process and lower the cost linked with sterilization, maintenance, and cleaning of steel bioreactors. In biopharmaceuticals, single-use bioprocessing solutions are used in several applications like storage, filtration, mixing, and purification.
Additionally, the rapidly growing geriatric population across the globe will fuel industry growth in the times to come. As per a report by United Nations, by 2050, it is projected that close to 1.5 billion of the global population will be 65 years of age or above. The geriatric population is highly prone to several chronic diseases and hence the need and consumption of biopharmaceutical medicines will rise considerably, further propelling the growth of the global single-use bioprocessing market.
The development of automation in the bioprocessing industry has emerged as one of the notable trends drastically increasing the efficiency of biomanufacturing. By allowing prediction and process parameters, the adoption of analytical models based on big data and machine learning is set to drive product yields.
The onset of the COVID-19 pandemic drove biopharmaceutical companies globally to develop effective and reliable vaccines in response to the lethal infection. In the race to develop the most effective vaccine against coronavirus, several leading manufacturers of single-use bioprocessing solutions joined hands with companies to develop medicines and vaccines.
Safe to say, burgeoning investments in single-use bioprocesses systems for R&D in order to develop sustainable solutions will continue to boost market growth across the globe in the times to come.
In the context of product, simple and peripheral elements recorded the highest demand supported by constant innovations in the product along with the rising adoption of bioprocessing operations in the manufacturing process. Under simple and peripheral elements, the product finds maximum application in connectors, filters, tubing, and transfer systems since tubing and connectors are offered by most single-use suppliers in compatible mode with single-use bags, bioreactors, and other bioprocessing apparatus.
In addition to above, media bags and containers have also witnessed considerable popularity owing to its use in a number of bioprocessing processes. Additionally, single-use containers find use in many critical liquid-handling applications in the biomanufacturing and biopharmaceutical industries. Additionally, single-use bioprocessing technologies are used in the production of monoclonal antibodies (mAb).
Based on workflow insights, upstream bioprocessing has witnessed notable traction supplemented by constant developments and advancements in upstream bioprocessing technologies. One such example is advanced products such as Ambr 15 micro-bioreactor system offered by Sartorius AG. They are known to offer high-throughput upstream process development along with efficient cell culture processing and media and feed optimization with automated experimental setup and sampling.
Considering end-use, the rapid rise in the number of biopharmaceutical manufacturers has led to the demand for single-use bioprocessing systems. High disposable income among people along with the need for effective and advanced medication to tackle some of the leading chronic diseases. Notably, over 80% of biopharmaceutical plants have adopted the use of single-use bioprocessing systems since it is cost-effective, reliable, and efficient. Growing R&D in the biopharmaceutical industry to develop advanced medication along with the improvement in the healthcare sector across the globe will continue to complement the segmental growth in the times to come.
On the basis of region, North America emerged as a hotbed for single-use bioprocessing companies due to the rapid growth and development of the biopharmaceutical sector in the region. Moreover, the outbreak of the coronavirus pandemic has stimulated the government to heavily invest in the R&D of COVID-19 vaccines, drugs, and diagnostic tests. For example, the U.S. government-sanctioned funds to accelerate the development of COVID-19 vaccines and medicines. Additionally, the presence of key players, largescale production units, increased healthcare expenditure, growing adoption of disposables, and a highly developed healthcare infrastructure are some of the leading factors widening the regional market scope.
The Asia Pacific has also showcased potential growth opportunities due to the rapidly expanding biopharmaceutical market in countries like India, Japan, and China. Moreover, surging investments made by biotechnology and pharmaceutical entities coupled with the rapid growth of contract manufacturers will lead to the emergence of Asia Pacific as a leading manufacturing hub for pharmaceuticals. Hence the region will significantly contribute towards the growth of single-use bioprocessing market in the ensuing years.
Research Support Specialist, USA